Kynos Therapeutics Announces The Expansion Of Its Leadership Team With The Appointment of Jonathan Savidge as CEO
November 11, 2022
Edinburgh UK – Kynos Therapeutics Ltd, an immune-metabolic company with world-leading expertise in the kynurenine pathway and kynurenine 3-monooxygenase (KMO) biology, today announced the appointment